MARKET

SCTX

SCTX

SCRIBE THERAPEUTICS INC
NASDAQ
17.96
-1.34
-6.94%
After Hours: 17.96 0 0.00% 19:54 10/22 EDT
OPEN
19.11
PREV CLOSE
19.30
HIGH
19.11
LOW
16.40
VOLUME
641.46K
TURNOVER
--
52 WEEK HIGH
39.60
52 WEEK LOW
13.50
MARKET CAP
340.01M
P/E (TTM)
-13.2507
1D
5D
1M
3M
1Y
5Y
1D
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
Seeking Alpha · 4d ago
Weekly Report: what happened at SCTX last week (1012-1016)?
Weekly Report · 4d ago
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst
Seeking Alpha · 10/15 13:06
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
Benzinga · 10/14 14:02
Weekly Report: what happened at SCTX last week (1005-1009)?
Weekly Report · 10/12 10:41
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
Benzinga · 10/06 15:46
Weekly Report: what happened at SCTX last week (0928-1002)?
Weekly Report · 10/05 10:40
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 09/30 17:06
More
About SCTX
Scribe Therapeutics, Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. It focuses on cardiovascular and metabolic (CVM) diseases with initial programs to address the key drivers of atherosclerotic cardiovascular disease (ASCVD). The Company's lead product candidate, STX-1150, is an epigenetic silencing therapy that is based on its ELXR technology and is designed to durably lower LDL-C for years to decades by repressing the expression of PCSK9, a genetically and clinically validated target. STX-1150 is designed to achieve long-lasting therapeutic benefit without permanently altering the underlying DNA sequence. Its pipeline also includes STX-1200 and STX-1400, target two additional lipid drivers of ASCVD, elevated Lp(a) and severely high triglycerides, by editing the LPA and APOC3 genes, respectively.

Webull offers Scribe Therapeutics, Inc. stock information, including NASDAQ: SCTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCTX stock methods without spending real money on the virtual paper trading platform.